Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.

U.S. Senator Jacky Rosen announced that 15 additional medications have been selected for Medicare drug pricing negotiations, aiming to reduce costs for seniors

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.

Hospitals are also seeing higher uncompensated care as individuals lose Medicaid coverage or decide not to purchase health insurance. If there are changes to the health insurance exchanges, more people could end up uninsured. Hospitals across the country, and particularly safety-net hospitals, are preparing for the worst.

Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.

Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Among the dozens of Biden-era executive orders he rescinded on day one, President Trump nixed one that aimed to explore new health care payment models that would lower prescription costs for

President Trump has rolled back a Biden-era executive order aimed at lowering prescription drug costs for Americans, raising concerns among Medicare and Medicaid recipients. FOX 5’s Linda Schmidt looks at what this means for patients and what impact it could have on existing policies,

Among the dozens of Biden-era executive orders he rescinded on day one, President Trump nixed one that aimed to explore new health care payment models that would lower prescription costs for Medicare and Medicaid beneficiaries.